Verona Pharma plc
VRNA
$105.27
$0.070.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 1,127.95% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 1,127.95% | -- |
| Cost of Revenue | -- | -- | -- | 56.94% | -- |
| Gross Profit | -- | -- | -- | 4,436.61% | -- |
| SG&A Expenses | 126.52% | 224.24% | 197.40% | 186.87% | 190.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.80% | 246.03% | 190.84% | 156.77% | 124.13% |
| Operating Income | 58.21% | -84.08% | -127.23% | -149.44% | -125.93% |
| Income Before Tax | 41.03% | -147.97% | -202.68% | -202.71% | -142.18% |
| Income Tax Expenses | 368.62% | 781.14% | 2,070.68% | 254.05% | 205.91% |
| Earnings from Continuing Operations | 35.28% | -158.50% | -218.96% | -203.27% | -142.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.28% | -158.50% | -218.96% | -203.27% | -142.89% |
| EBIT | 58.21% | -84.08% | -127.23% | -149.44% | -125.93% |
| EBITDA | 58.79% | -84.56% | -127.96% | -150.34% | -126.83% |
| EPS Basic | 36.41% | -153.11% | -210.03% | -192.31% | -123.63% |
| Normalized Basic EPS | 40.56% | -136.49% | -187.80% | -202.22% | -128.66% |
| EPS Diluted | 35.94% | -147.45% | -200.90% | -198.38% | -126.05% |
| Normalized Diluted EPS | 40.02% | -136.49% | -187.80% | -202.22% | -128.66% |
| Average Basic Shares Outstanding | 4.10% | 3.21% | 2.87% | 3.59% | 7.07% |
| Average Diluted Shares Outstanding | 5.73% | 3.21% | 2.87% | 3.59% | 7.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |